Emerging Targets, Novel Directions, and Innovative Approaches in Thrombosis Therapy

Area of Science:

• Pharmacology
• Hematology
• Biomedical Engineering

Background:

• Current antithrombotic drugs (antiplatelet, anticoagulant, fibrinolytic) have significant bleeding risks.
• Platelets, coagulation cascade, and inflammatory pathways are key in thrombosis.
• Need for safer antithrombotic therapies with reduced side effects.

Purpose of the Study:

• To review novel antithrombotic drug targets and formulations.
• To discuss the mode of action and efficacy of emerging therapies.
• To highlight existing challenges and future research directions.

Main Methods:

• Focus on platelet surface receptors, intracellular signaling, and metabolism.
• Investigation of contact system molecules (FXIa, FXIIa) in anticoagulation.
• Exploration of inflammatory pathways, including inflammasome targeting.
• Evaluation of antithrombotic nanomedicines for targeted drug delivery.

Main Results:

• New antithrombotic strategies target platelets, contact system, and inflammation.
• FXIa and FXIIa inhibitors represent a promising direction for anticoagulation.
• Inflammasome-targeting drugs are emerging as a potential therapeutic avenue.
• Nanomedicines offer improved drug delivery and reduced adverse effects.

Conclusions:

• Significant progress in identifying new antithrombotic targets and drug formulations.
• Emerging therapies show potential for improved efficacy and safety.
• Further research is needed to overcome limitations and optimize clinical application.